Highlights
- Imugene has presented positive imaging data on its oncolytic virotherapy candidate, CHECKvacc (CF33-hNIS-antiPDL1) at the AACR Annual Meeting 2023 in Orlando, Florida.
- The data was presented by Dr Jamie Rand, an Assistant Professor in the Division of Breast Surgery at the City of Hope’s Department of Surgery.
- The abstract was titled “hNIS imaging data from a first-inhuman trial of the oncolytic virus CF33-hNIS-antiPD-L1 in patients with triple negative breast cancer”.
- The data highlights that CF33-hNIS-antiPD-L1 is safe and well tolerated at dose levels 1 through 3.
ASX-listed clinical-stage immune-oncology company Imugene Limited (ASX:IMU) announced that the positive imaging data on its oncolytic virotherapy candidate, CHECKvacc (CF33-hNIS-antiPDL1) has been featured at the AACR Annual Meeting 2023 in Orlando, Florida.
The data was presented by Dr Jamie Rand, an Assistant Professor in the Division of Breast Surgery at the City of Hope’s Department of Surgery. The abstract was titled “hNIS imaging data from a first-inhuman trial of the oncolytic virus CF33-hNIS-antiPD-L1 in patients with triple negative breast cancer”.
What is CF33-hNIS-antiPDL1?
CF33-hNIS-antiPDL1 is an immune checkpoint inhibitor armed chimeric vaccinia poxvirus from the lab of CF33 inventor Professor Yuman Fong, Chair of Sangiacomo Family Chair in Surgical Oncology at City of Hope, and an expert in the oncolytic virus field.
Oncolytic viruses (OVs) have been developed to selectively eliminate tumour cells and trigger the immune system against cancer cells, with the potential to boost clinical response and survival.
Data & image source: Company update
IMU shares were trading at AU$0.137 in the early hours of 20 April 2023.